European guideline and expert statements on the management of narcolepsy in adults and children

CLA Bassetti, U Kallweit, L Vignatelli… - European journal of …, 2021 - Wiley Online Library
Background and aim Narcolepsy is an uncommon hypothalamic disorder of presumed
autoimmune origin that usually requires lifelong treatment. This paper aims to provide …

The integrated brain network that controls respiration

F Krohn, M Novello, RS van der Giessen, CI De Zeeuw… - Elife, 2023 - elifesciences.org
Respiration is a brain function on which our lives essentially depend. Control of respiration
ensures that the frequency and depth of breathing adapt continuously to metabolic needs. In …

[HTML][HTML] Oral orexin receptor 2 agonist in narcolepsy type 1

Y Dauvilliers, E Mignot, R del Río Villegas… - … England Journal of …, 2023 - Mass Medical Soc
Background Narcolepsy type 1 is caused by severe loss or lack of brain orexin
neuropeptides. Methods We conducted a phase 2, randomized, placebo-controlled trial of …

Understanding and approaching excessive daytime sleepiness

L Pérez-Carbonell, E Mignot, G Leschziner… - The Lancet, 2022 - thelancet.com
Excessive daytime sleepiness (EDS) is a public health issue. However, it remains largely
undervalued, scarcely diagnosed, and poorly supported. Variations in the definition of EDS …

Sleep disorders and cancer: State of the art and future perspectives

MP Mogavero, LM DelRosso, F Fanfulla, O Bruni… - Sleep medicine …, 2021 - Elsevier
A bidirectional connection between sleep and cancer exists; however, the specific
associations between individual sleep disorders and particular tumors are not very clear. An …

Epigenetic silencing of selected hypothalamic neuropeptides in narcolepsy with cataplexy

A Seifinejad, M Ramosaj, L Shan, S Li… - Proceedings of the …, 2023 - National Acad Sciences
Narcolepsy with cataplexy is a sleep disorder caused by deficiency in the hypothalamic
neuropeptide hypocretin/orexin (HCRT), unanimously believed to result from autoimmune …

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

R Evans, H Kimura, R Alexander… - Proceedings of the …, 2022 - National Acad Sciences
Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons.
Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin …

[HTML][HTML] Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts

GJ Lammers, CLA Bassetti, L Dolenc-Groselj… - Sleep medicine …, 2020 - Elsevier
The aim of this European initiative is to facilitate a structured discussion to improve the next
edition of the International Classification of Sleep Disorders (ICSD), particularly the chapter …

Excessive daytime sleepiness: a clinical review

KD Gandhi, MP Mansukhani, MH Silber… - Mayo Clinic …, 2021 - Elsevier
Excessive daytime sleepiness (EDS) is a highly prevalent condition that is associated with
significant morbidity. The causes of EDS are varied, and include inadequate sleep, sleep …

Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy

H Ito, N Fukatsu, SM Rahaman… - Proceedings of the …, 2023 - National Acad Sciences
Narcolepsy is a sleep disorder caused by deficiency of orexin signaling. However, the
neural mechanisms by which deficient orexin signaling causes the abnormal rapid eye …